NASDAQ:IRON - Nasdaq - US2546041011 - Common Stock - Currency: USD
54.53
+0.18 (+0.33%)
The current stock price of IRON is 54.53 USD. In the past month the price decreased by -4.32%. In the past year, price decreased by -16.11%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
DISC MEDICINE INC
321 Arsenal Street, Suite 101
Watertown MASSACHUSETTS US
Employees: 78
Company Website: https://www.discmedicine.com/
Investor Relations: http://www.ir.discmedicine.com/
Phone: 16176749274
The current stock price of IRON is 54.53 USD. The price increased by 0.33% in the last trading session.
The exchange symbol of DISC MEDICINE INC is IRON and it is listed on the Nasdaq exchange.
IRON stock is listed on the Nasdaq exchange.
17 analysts have analysed IRON and the average price target is 96.71 USD. This implies a price increase of 77.36% is expected in the next year compared to the current price of 54.53. Check the DISC MEDICINE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
DISC MEDICINE INC (IRON) has a market capitalization of 1.87B USD. This makes IRON a Small Cap stock.
DISC MEDICINE INC (IRON) currently has 78 employees.
DISC MEDICINE INC (IRON) has a support level at 54.34 and a resistance level at 56.3. Check the full technical report for a detailed analysis of IRON support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IRON does not pay a dividend.
DISC MEDICINE INC (IRON) will report earnings on 2025-03-19, after the market close.
DISC MEDICINE INC (IRON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.91).
The outstanding short interest for DISC MEDICINE INC (IRON) is 8.31% of its float. Check the ownership tab for more information on the IRON short interest.
ChartMill assigns a fundamental rating of 3 / 10 to IRON. While IRON has a great health rating, there are worries on its profitability.
Over the last trailing twelve months IRON reported a non-GAAP Earnings per Share(EPS) of -3.91. The EPS decreased by -4.55% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -20.9% | ||
ROE | -22.11% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 86% to IRON. The Buy consensus is the average rating of analysts ratings from 17 analysts.